
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 22, 2024, titled "Zydus receives approval from COFEPRIS of Mexico to market Bhava (Bevacizumab biosimilar) to treat various cancers".
Filed with NSE ·

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 22, 2024, titled "Zydus receives approval from COFEPRIS of Mexico to market Bhava (Bevacizumab biosimilar) to treat various cancers".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences